Cargando…
Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
To investigate whether metformin add-on to the continuous subcutaneous insulin infusion (Met + CSII) therapy leads to a significant reduction in insulin doses required by type 2 diabetes (T2D) patients to maintain glycemic control, and an improvement in glycemic variation (GV) compared to CSII only...
Autores principales: | Li, Feng-fei, Liu, Bing-li, Yin, Guo-ping, Yan, Reng-na, Zhang, Dan-feng, Wu, Jin-dan, Ye, Lei, Su, Xiao-fei, Ma, Jian-hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018811/ https://www.ncbi.nlm.nih.gov/pubmed/29946148 http://dx.doi.org/10.1038/s41598-018-27950-9 |
Ejemplares similares
-
Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial
por: Li, Feng-fei, et al.
Publicado: (2016) -
Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy
por: Li, Feng-fei, et al.
Publicado: (2018) -
Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022) -
Continuous subcutaneous insulin infusion: practical issues
por: Saboo, Banshi D., et al.
Publicado: (2012) -
Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial
por: Li, Feng-fei, et al.
Publicado: (2016)